Horn, L., & Steins, M. (2017). Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). Journal of clinical oncology, 35(35), . https://doi.org/10.1200/JCO.2017.74.3062
Chicago-Zitierstil (17. Ausg.)Horn, Leora, und Martin Steins. "Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non-small-cell Lung Cancer: Two-year Outcomes from Two Randomized, Open-label, Phase III Trials (CheckMate 017 and CheckMate 057)." Journal of Clinical Oncology 35, no. 35 (2017). https://doi.org/10.1200/JCO.2017.74.3062.
MLA-Zitierstil (9. Ausg.)Horn, Leora, und Martin Steins. "Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non-small-cell Lung Cancer: Two-year Outcomes from Two Randomized, Open-label, Phase III Trials (CheckMate 017 and CheckMate 057)." Journal of Clinical Oncology, vol. 35, no. 35, 2017, https://doi.org/10.1200/JCO.2017.74.3062.